Science
The problem: Less than 1% of next-generation therapeutics cross cellular barriers efficiently
Large molecules do not cross cell- or endosomal membranes efficiently. Therefore, intracellular target engagement is inefficient. This leads to limited new treatment options for patients, despite validated and promising disease targets. There is a high need for improved intracellular delivery of next-generation oligonucleotide therapeutics (siRNAs and ASOs).
Our solution: Harnessing the power of endosomal escape enhancers evolved in plant biology
Sapreme has selected a unique class of plant secondary metabolites (glycosylated triterpenoids) that specifically enhance delivery of large molecules to the cellular cytoplasm by mediating endosomal escape. Through advanced chemical modification of these natural compounds, Sapreme has developed a proprietary technology platform (SPT) with optimized medicinal properties. Our SPT platform selectively enhances receptor-targeted delivery to endosomes and enables pH-driven endosomal release of the therapeutic. Endosomal targeting and proprietary linker technology means that SPT remains inactive in circulation and has unprecedented endosomal escape potency and tolerability.
Team
Executive Management Team
Miriam Bujny
CDO
Ruben Postel
CSO & Founder
Laurens van Pinxteren
VP CMC
Board of Directors
Jeanne Bolger
Chair
Marco Timmers
CEO
Karl Rothweiler
Hendrik Zonnenberg
Scientific Advisory Board
News & Events
Press Releases
Bilthoven, The Netherlands
Sapreme, a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD). Additionally, the company has established its Scientific Advisory Board (SAB), comprised of experts in diseases with high unmet medical need, as well as the rapidly expanding field of RNA delivery. Read the full press release here.
Upcoming Events
No events scheduled ahead
About Sapreme:
Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues.
For Media Inquiries, please contact:
Trophic Communications
Desmond James or Valeria Fisher | +49 151 67859086 or +49 175 8041816 | sapreme@trophic.eu
Careers
Open applications welcome
If you are a talented individual interested in contributing to our mission, please send your resume to careers@sapreme-technologies.com
Contact
Telephone
+31 30 760 09 76 (Main office Desk)
Address
Antonie van Leeuwenhoeklaan 9
USP Bilthoven A12-1
3721 MA Bilthoven
The Netherlands